ADVERTISEMENT

clinical trials, drug development, cancer, biobusiness

PARP Inhibitors Are Improving the Outlook of Hard-to-Treat Cancers
Vicki Brower | Apr 1, 2018 | 9 min read
With three recent FDA approvals, and a number of Phase 3 trials ongoing, the drugs are seeing a surge in interest.
Take Two of These
Bob Grant | Jun 22, 2011 | 6 min read
Drugmakers are teaming up to test the disease-fighting power of combination therapies earlier in the development cycle than ever before.
ADVERTISEMENT